10 months ago
LLY
AnalystsEvan SeigermanEvan Seigerman's Stock Forecasts
AnalystsEvan Seigerman
Analyst Ranking
Bottom 15%
#4220 out of 4914 analysts
Average Return
-0.83%
Win Rate
41%32 out of 78
Risk vs Reward
Poor
Good
Evan Seigerman's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Disc Medicine IncIRON | +165.37% | $22.84 | $60.61 | 2023-03-23 - 2024-03-22 | Buy |
Eli Lilly & CoLLY | +71.55% | $428.44 | $734.97 | 2023-05-04 - 2024-05-03 | Buy |
Structure Therapeutics IncGPCR | +69.29% | $25.56 | $43.27 | 2023-02-28 - 2024-02-28 | Buy |
Eli Lilly & CoLLY | +60.64% | $526.23 | $845.31 | 2023-08-09 - 2024-08-08 | Buy |
Gilead Sciences IncGILD | +47.30% | $73.66 | $108.50 | 2024-08-09 - 2025-06-20 | Buy |
Evan Seigerman Analyst Color
Get additional color on Evan Seigerman's coverage of popular stocks
a year ago
LLY
a year ago
LLY
2 years ago
LLY
2 years ago
LLY
4 years ago
PFE
Evan Seigerman's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Disc Medicine IncIRON | 5 | Buy | $120.00 | +132.51% | Maintains | a month ago |
Neurocrine Biosciences IncNBIX | 11 | Hold | $115.00 | -9.13% | Maintains | 2 months ago |
Gilead Sciences IncGILD | 13 | Buy | $120.00 | +10.60% | Maintains | 2 months ago |
Biogen IncBIIB | 14 | Hold | $139.00 | +9.41% | Maintains | 4 months ago |
Vertex Pharmaceuticals IncVRTX | 13 | Buy | $545.00 | +23.62% | Maintains | 5 months ago |
Bristol Myers Squibb CoBMY | 11 | Hold | $61.00 | +30.17% | Maintains | 7 months ago |
Incyte CorpINCY | 8 | Sell | $52.00 | -24.04% | Reiterates | 8 months ago |
Eli Lilly & CoLLY | 8 | Buy | $1,101.00 | +44.35% | Maintains | 10 months ago |
Structure Therapeutics IncGPCR | 1 | Buy | $40.00 | N/A | Initiates Coverage On | 2 years ago |
Mirati Therapeutics IncMRTX | 4 | Hold | $59.00 | N/A | Downgrades | 3 years ago |
Replimune Group IncREPL | 1 | Buy | $40.00 | N/A | Maintains | 3 years ago |
Regeneron Pharmaceuticals IncREGN | 9 | Buy | $788.00 | N/A | Maintains | 3 years ago |
Nuvation Bio IncNUVB | 2 | Hold | $2.50 | N/A | Downgrades | 3 years ago |
Candel Therapeutics IncCADL | 2 | Buy | $12.00 | N/A | Maintains | 3 years ago |
Pfizer IncPFE | 1 | Buy | $60.00 | N/A | Initiates Coverage On | 4 years ago |
Amgen IncAMGN | 4 | Hold | $228.00 | N/A | Initiates Coverage On | 4 years ago |
Ikena Oncology IncIKNA | 1 | Buy | $30.00 | N/A | Initiates Coverage On | 4 years ago |
Satsuma Pharmaceuticals IncSTSA | 2 | Hold | $6.50 | N/A | Upgrades | 4 years ago |
Galera Therapeutics IncGRTX | 2 | Buy | $15.00 | N/A | Upgrades | 5 years ago |
Aimmune Therapeutics IncAIMT | 3 | Hold | $34.50 | N/A | Maintains | 5 years ago |
Talphera IncTLPH | 5 | Sell | $16.80 | N/A | Maintains | 5 years ago |
Macrogenics IncMGNX | 1 | Buy | $13.00 | N/A | Maintains | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.